ATE196769T1 - Kontrollierte oxidation von mikrobiell herstellten, cystein-enthaltenden proteinen - Google Patents
Kontrollierte oxidation von mikrobiell herstellten, cystein-enthaltenden proteinenInfo
- Publication number
- ATE196769T1 ATE196769T1 AT93203286T AT93203286T ATE196769T1 AT E196769 T1 ATE196769 T1 AT E196769T1 AT 93203286 T AT93203286 T AT 93203286T AT 93203286 T AT93203286 T AT 93203286T AT E196769 T1 ATE196769 T1 AT E196769T1
- Authority
- AT
- Austria
- Prior art keywords
- synthetic
- oxidizing agent
- microbially produced
- containing proteins
- controlled oxidation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59435184A | 1984-03-28 | 1984-03-28 | |
US06/661,902 US4530787A (en) | 1984-03-28 | 1984-10-17 | Controlled oxidation of microbially produced cysteine-containing proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE196769T1 true ATE196769T1 (de) | 2000-10-15 |
Family
ID=27081941
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT85103559T ATE108186T1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. |
AT93203286T ATE196769T1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte oxidation von mikrobiell herstellten, cystein-enthaltenden proteinen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT85103559T ATE108186T1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. |
Country Status (5)
Country | Link |
---|---|
US (1) | US4530787A (de) |
EP (2) | EP0606673B1 (de) |
AT (2) | ATE108186T1 (de) |
CA (1) | CA1233172A (de) |
DE (3) | DE156354T1 (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
JPS60115528A (ja) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | ヒトインタ―ロイキン―2蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物 |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4761375A (en) * | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
US5248769A (en) * | 1985-06-26 | 1993-09-28 | Cetus Oncology Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
US4933433A (en) * | 1986-01-31 | 1990-06-12 | E. I. Du Pont De Nemours And Company | Recombinant interleukin-2 composition and process for making it |
CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
DE3611817A1 (de) * | 1986-04-08 | 1987-10-15 | Boehringer Mannheim Gmbh | Verfahren zur renaturierung von proteinen |
US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4777242A (en) * | 1986-10-10 | 1988-10-11 | Phillips Petroleum Company | Purification of recombinant tumor necrosis factor |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
CA1339757C (en) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
AU621051B2 (en) * | 1987-04-28 | 1992-03-05 | Amgen, Inc. | Method for purifying granulocyte-macrophage colony stimulating factor |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
DE3855986T2 (de) * | 1987-05-11 | 1998-02-05 | Chiron Corp | Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen |
US4801691A (en) * | 1987-05-15 | 1989-01-31 | International Minerals & Chemical Corp. | Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions |
US4985544A (en) * | 1987-08-04 | 1991-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for renaturing fish growth hormone |
US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US5759815A (en) * | 1988-02-11 | 1998-06-02 | Creative Biomolecules, Inc. | Production of platelet derived growth factor (PDGF) an muteins thereof |
CA1340586C (en) * | 1988-09-23 | 1999-06-08 | Cetus Corporation | Process for recovering microbially produced interferon-beta |
JP2682061B2 (ja) * | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
US5204256A (en) * | 1989-09-06 | 1993-04-20 | Behringwerke Aktiengesellschaft | Process for the purification of plasminogen activator inhibitor 2 (pai-2) |
US5023323A (en) * | 1990-09-12 | 1991-06-11 | Monsanto Company | Method of somatotropin naturation |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
JP3021040B2 (ja) * | 1990-11-23 | 2000-03-15 | ヘキスト・マリオン・ルセル | 少なくとも1個の分子内ジスルフィド結合を含有する蛋白質を相当する還元された組替え蛋白質を5.0以下のpHで酸化することによって製造する方法 |
DE4105480A1 (de) * | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
US20030171292A1 (en) * | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
AU687763B2 (en) * | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
WO2002079157A1 (en) | 2001-03-29 | 2002-10-10 | Schering Corporation | Aryl oxime-piperazines useful as ccr5 antagonists |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
MXPA04003547A (es) * | 2001-10-15 | 2004-07-22 | Chiron Corp | Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido. |
AU2004224191A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
RU2006104023A (ru) * | 2003-07-11 | 2006-07-27 | Шеринг Акциенгезельшафт (De) | УЛУЧШЕННЫЕ РЕКОМБИНАНТНЫЕ ПОЛИПЕПТИДЫ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА -БЕТА-1b |
PT1682178E (pt) | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
US20080286279A1 (en) * | 2004-03-17 | 2008-11-20 | Chiron Corporation | Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi) |
ES2318916B1 (es) * | 2005-02-07 | 2010-03-22 | Chiron Corporation | Procedimiento para preparar aldesleukina para uso farmaceutico. |
KR20080056220A (ko) | 2005-10-19 | 2008-06-20 | 에프. 호프만-라 로슈 아게 | 페닐-아세트아마이드 nnrt 저해제 |
PT2057125E (pt) | 2006-08-16 | 2011-05-31 | Hoffmann La Roche | Inibidores n?o nucle?sidos de transcriptase inversa |
ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
WO2008145562A1 (en) | 2007-05-30 | 2008-12-04 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
WO2009045553A1 (en) * | 2007-10-05 | 2009-04-09 | Barofold, Inc. | High pressure treatment of aggregated interferons |
WO2009080534A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
NZ601759A (en) | 2010-03-17 | 2013-07-26 | Biogenerix Gmbh | Method for obtaining biologically active recombinant human g-csf |
WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EP3766513A1 (de) | 2011-03-11 | 2021-01-20 | Assistance Publique Hôpitaux de Paris | Niedrige il-2 dosierungen zur behandlung von vaskulitis |
WO2013058762A1 (en) * | 2011-10-21 | 2013-04-25 | Tanvex Biologics Corp. | Separation of acetylated proteins from unacetylated proteins |
US10183061B2 (en) | 2013-06-25 | 2019-01-22 | Icm (Institut Du Cerveau Et De La Moelle Epiniere) | Boosting Treg cells for treating Alzheimer disease and related disorders |
EP3049445A4 (de) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2-fusionsproteine und verwendungen davon |
EP2918285A1 (de) | 2014-03-11 | 2015-09-16 | Université Pierre et Marie Curie (Paris 6) | Interleukin-2 zur Behandlung einer Lebensmittelallergie |
WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
US10457716B2 (en) | 2014-08-06 | 2019-10-29 | University Of Notre Dame Du Lac | Protein folding and methods of using same |
US10806773B2 (en) | 2014-10-09 | 2020-10-20 | Dana-Farber Cancer Institute, Inc. | Multiple-variable IL-2 dose regimen for treating immune disorders |
AU2016341241B9 (en) * | 2015-10-22 | 2021-11-18 | Iltoo Pharma | Pharmaceutical compositions of IL-2 |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
EP3641814A4 (de) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | Verwendungen und verfahren für il-2-superagonisten, agonisten und fusionen davon |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
EP3836954A1 (de) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
AU2021207652B2 (en) | 2020-01-14 | 2023-08-03 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4114440A1 (de) | 2020-03-06 | 2023-01-11 | Centre Hospitalier Universitaire de Nimes | Niedrigdosiertes humanes interleukin-2 zur behandlung von amyotropher lateralsklerose |
WO2024121173A1 (en) | 2022-12-05 | 2024-06-13 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061538A (en) * | 1973-04-04 | 1977-12-06 | Sandoz Ltd. | Enzymatically oxidizing interferon |
CH648331A5 (de) * | 1979-07-31 | 1985-03-15 | Hoffmann La Roche | Homogenes fibroblasten-interferon und dessen herstellung. |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4405601A (en) * | 1981-05-21 | 1983-09-20 | Cancer Research Center | Extraction and purification of biologically active lymphokines |
US4478744A (en) * | 1982-01-25 | 1984-10-23 | Sherwood Medical Company | Method of obtaining antibodies |
US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
EP0091539B2 (de) * | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen |
DE3378128D1 (en) * | 1982-04-20 | 1988-11-03 | Sloan Kettering Inst Cancer | Purification of interleukin 2 |
JPS58201794A (ja) * | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
FI82266C (fi) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
GR79124B (de) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
WO1984003711A1 (en) * | 1983-03-25 | 1984-09-27 | Celltech Ltd | A process for the production of a protein |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
-
1984
- 1984-10-17 US US06/661,902 patent/US4530787A/en not_active Expired - Lifetime
- 1984-11-28 CA CA000468868A patent/CA1233172A/en not_active Expired
-
1985
- 1985-03-26 EP EP93203286A patent/EP0606673B1/de not_active Expired - Lifetime
- 1985-03-26 EP EP85103559A patent/EP0156354B1/de not_active Expired - Lifetime
- 1985-03-26 AT AT85103559T patent/ATE108186T1/de not_active IP Right Cessation
- 1985-03-26 DE DE198585103559T patent/DE156354T1/de active Pending
- 1985-03-26 DE DE3588226T patent/DE3588226D1/de not_active Expired - Lifetime
- 1985-03-26 AT AT93203286T patent/ATE196769T1/de not_active IP Right Cessation
- 1985-03-26 DE DE3587873T patent/DE3587873T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE156354T1 (de) | 1986-03-20 |
DE3588226D1 (de) | 2000-11-09 |
EP0156354B1 (de) | 1994-07-06 |
EP0606673A2 (de) | 1994-07-20 |
EP0156354A3 (en) | 1987-10-28 |
CA1233172A (en) | 1988-02-23 |
DE3587873D1 (de) | 1994-08-11 |
EP0606673A3 (de) | 1995-01-25 |
US4530787B1 (de) | 1993-07-20 |
EP0156354A2 (de) | 1985-10-02 |
US4530787A (en) | 1985-07-23 |
DE3587873T2 (de) | 1994-10-20 |
ATE108186T1 (de) | 1994-07-15 |
EP0606673B1 (de) | 2000-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4530787B1 (de) | ||
ES549135A0 (es) | Un metodo para oxidar una proteina recombinante totalmente reducida | |
DE69031219D1 (de) | Stabile zusammensetzungen von askorbinsäure | |
ES8603271A1 (es) | Un metodo de producir una composicion de interleuquina-2 | |
BE904831A (fr) | Composition d'activateur tissulaire du plasminogene. | |
DK107086D0 (da) | Peptider | |
DE3781031D1 (de) | Markierung von traegermolekuelen mit metallionen. | |
DE3852140D1 (de) | Produktion von Proteinen in aktiven Formen. | |
DE3681185D1 (de) | Methode zur aufloesung und naturation von somatotropin. | |
ATE147167T1 (de) | Oxidative denaturierung von eiweissanalyten | |
BR8507127A (pt) | Solucao colutoria bucal | |
ATE82857T1 (de) | Interleukin-2-zusammensetzungen. | |
EP0312358A3 (de) | Methode zur Herstellung intramolekularer Disulfidbrücken in rekombinanten Proteinen in Gegenwart eines Denaturierungsmittels | |
ATE49214T1 (de) | Platinkomplexe von aliphatischen tricarbonsaeuren. | |
ZA844990B (en) | Low ph hair conditioning and neutralizer conditioning compositions containing amine oxides | |
CA1263590C (en) | CYANIDE-FREE REAGENT FOR THE DETERMINATION OF HEMOGLOBIN | |
AU564269B2 (en) | Compositions containing s-adenosyl-l methionine | |
IE822714L (en) | Preparation of 1-formyl congeners of indole-dihydroindole¹dimers | |
EP0063328A3 (de) | Sekretin enthaltende Zusammensetzungen und Verfahren zur Verhütung der Adsorption von Sekretin | |
ATE82269T1 (de) | Verfahren zur herstellung von 1-pyrazolinen. | |
KR950018051A (ko) | 싸이모신-알파와 다른 싸이토킨이 융합된 융합 단백질 | |
ATE31623T1 (de) | Injizierbare zusammensetzungen von bbm-928a. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
EELA | Cancelled due to lapse of time |